8-K/A: Tevogen Bio Holdings Secures $8 Million Investment and Restructures Debt in Business Combination

Tevogen Bio Holdings finalized a business combination, secured an $8 million investment through a Series A Preferred Stock offering, and restructured over $4.2 million in liabilities.

Summary

• Tevogen Bio Holdings Inc. completed a business combination with Semper Paratus Acquisition Corporation, resulting in the renaming of Semper Paratus to Tevogen Bio Holdings Inc.
• The company entered into a securities purchase agreement for $8 million through the sale of Series A Preferred Stock, with $2 million due on February 15, 2024, and the remaining $6 million by March 16, 2024.
• The Series A Preferred Stock is convertible into 2,000,000 common shares and carries a 5% annual cumulative dividend, increasing by 2% each year.
• Tevogen also entered into an agreement with SSVK Associates, LLC, where SSVK assumed over $4.2 million in liabilities in exchange for Series B Preferred Stock.
• The Series B Preferred Stock is non-convertible, callable, and pays a 3.5% quarterly dividend, increasing by 0.25% each month after the first 30 days, up to a maximum of 7.5% per quarter.
• Additionally, the company issued 600,000 common shares to two financial institutions for capital markets advisory services.
• SSVK converted $1.5 million in loans to Semper Paratus into common stock, and Mr. Ajjarapu converted $240,000 in loans to SSVK into common stock.
• As part of the SSVK conversion, the company's obligation to pay $2 million to SSVK was reduced to $500,000.

Sentiment

Score: 7

Explanation: The document indicates positive financial activity with a capital raise and debt restructuring, but also includes some potential risks related to the terms of the preferred stock and potential dilution. Overall, the sentiment is moderately positive.

Positives

• The company successfully raised $8 million through the sale of Series A Preferred Stock.
• The restructuring of over $4.2 million in liabilities through the issuance of Series B Preferred Stock strengthens the company's balance sheet.
• The conversion of loans into equity reduces the company's debt burden.
• The company has secured capital markets advisory services through the issuance of common stock.

Negatives

• The Series A Preferred Stock is non-voting, which may limit the influence of the investor.
• The Series B Preferred Stock is non-convertible and callable, which may not be attractive to all investors.
• The company is issuing a significant number of shares, which could dilute existing shareholders.

Risks

• The Series A Preferred Stock has a call right if the common stock price exceeds $5.00, which could limit the investor's potential upside.
• The dividend rate on the Series B Preferred Stock increases over time, which could increase the company's financial obligations.
• The company is reliant on exemptions from registration for these transactions, which could pose regulatory risks.
• The company is dependent on the performance of the common stock to trigger the call right on the Series A Preferred Stock.

Future Outlook

The company will continue to execute its business plan following the completion of the business combination and the capital raise. The company will also be subject to ongoing obligations related to the preferred stock issuances.

Management Comments

• The company has not provided any direct quotes from management in this document.

Industry Context

This announcement reflects a common strategy for companies to raise capital and restructure debt following a business combination. The use of preferred stock with specific dividend and conversion terms is a typical approach in such transactions. The company is operating in the biotechnology sector, which often requires significant capital investment.

Comparison to Industry Standards

• The use of preferred stock with a cumulative dividend is a common method for raising capital in the biotech industry, similar to companies like XOMA Corporation and Agenus Inc.
• The conversion of debt into equity is a standard practice for companies looking to improve their balance sheet, similar to the restructuring efforts of companies like Sorrento Therapeutics.
• The issuance of shares for advisory services is a common practice in the financial industry, similar to the arrangements made by many companies during capital raises.
• The specific terms of the preferred stock, such as the dividend rates and conversion ratios, are tailored to the company's specific needs and the investor's requirements, which is typical in private placements.

Related Party Transactions

• The investor in the Series A Preferred Stock is an entity associated with Dr. Manmohan Patel, an existing investor and beneficial owner of more than 5% of the company's common stock.
• SSVK Associates, LLC, which assumed liabilities in exchange for Series B Preferred Stock, was the beneficial owner of more than 5% of the company's common stock, and Suren Ajjarapu, managing member of SSVK, is a member of the company's board of directors.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new common shares.
• Creditors of Semper Paratus will be paid through the dividend payments on the Series B Preferred Stock.
• The company's financial position is strengthened through the capital raise and debt restructuring.
• The company's long-term viability is improved through the business combination.

Next Steps

• The company will need to fulfill its obligations under the Series A and Series B Preferred Stock agreements.
• The company will need to manage the dividend payments on the preferred stock.
• The company will need to monitor the common stock price to determine if the call right on the Series A Preferred Stock is triggered.

Key Dates

Keywords

Preferred Stock, Business Combination, Capital Raise, Debt Restructuring, Convertible Securities, Equity Issuance, Merger, Tevogen Bio, Semper Paratus, SSVK Associates